Application of sulindac in preparation of medicine for treating autism

A technology for sulindac and autism, applied in the field of medicine, can solve problems affecting children's health and social stability, affecting children's physical and mental health and quality of life, and children's inability to integrate into society

Inactive Publication Date: 2014-03-12
XINXIANG MEDICAL UNIV
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Autism damages a wide range of areas during the growth and development of children, making most children unable to integrate into society, seriously affecting children's physical and mental health and quality of life; autism is a chronic disease,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sulindac in preparation of medicine for treating autism
  • Application of sulindac in preparation of medicine for treating autism
  • Application of sulindac in preparation of medicine for treating autism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Application of sulindac in the preparation of medicine for treating rigid limitation of behavior.

[0028] Establishment of experimental animals and VPA (sodium valproate) autism animal model.

[0029] Experimental animals: healthy adult Wistar male (300-350g) and female (200-250g) rats were purchased from the Department of Experimental Animals, Chinese Academy of Sciences (Shanghai), and were raised in the special animal room of the Department of Human Anatomy, Histology and Embryology, Fudan University. feed and drinking water. All experimental animal feeding and experimental procedures were strictly in accordance with the terms of protection of experimental animals of Fudan University.

[0030] The basic process of establishing the VPA autism rat model is as follows: several adult female and male Wistar rats were fed for several days under the conditions of periodic light (7:00AM-7:00PM), constant temperature 25°C and constant humidity 55%. Adapt it to the environm...

Embodiment 2

[0044] Application of sulindac in preparing medicine for treating social behavior disorder.

[0045] The establishment of experimental animals and VPA (sodium valproate) autism animal model is the same as in Example 1.

[0046] Experiment 7 Effect of sulindac on social interaction behavior of VPA autism animal model.

[0047] The effect of sulindac on the social behavior of autism model mice was tested by animal social interaction behavior. The social interaction behavior index uses two indicators: the time when the experimental rat enters the box where the new object is located and the box where the new rat is located, and the time when the experimental rat sniffs the new object and the new rat. The comparison of the number of times the rats entered the left box and the right box showed that there was no statistical difference among the three groups ( Figure 10 C), in this way, the influence of the three groups of rats on the box preference on the experimental results is e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of sulindac in preparation of a medicine for treating autism. The application of sulindac in preparation of the medicine for treating autism is characterized in that a VPA (Valproic Acid) autism animal model shows that sulindac is able to reduce abnormal behavior of an autistic, such as repeated mechanical behavior deficiency and human communication disorders; the primary culture neuron and VPA autism animal model verify the occurrence mechanism of autism as well as the functional mechanism of sulindac in treating autistic, and also prove that sulindac has oxidation resistance, and the oxidation resistance is related to down-regulating of the activity of a canonical Wnt signal channel. Therefore, sulindac is able to reduce the repeated mechanical behavior, abnormal behavior and human communication disorders of the autistic and can be used for preparing the medicine for treating autism.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of sulindac in the preparation of medicine for treating autism. Background technique [0002] Autism, also known as autism or autistic disorder, is a representative disease of pervasive developmental disorders. Autism is mainly manifested as three core symptoms: delayed language development, social behavior disorders, and rigid and limited behavior. Delayed language development refers to a complete or partial delay in the development of speech without an attempt to replace it with other means (such as gestures or imitation); in those who have a certain ability to speak, there is obvious impairment in the ability to raise topics and maintain conversations; Use stereotyped or repetitive language or idiosyncratic language that only you understand. Social behavior disorder refers to significant impairment in the use of nonverbal communication behavior; ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P25/00
Inventor 张应花孙永琨邓晓慧连辉贾云杰
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap